Clinical Drug Investigation

, Volume 9, Issue 1, pp 54–56 | Cite as

Effect of Pantoprazole on Ovulation Suppression by a Low-Dose Hormonal Contraceptive

  • M. V. Middle
  • F. O. Müller
  • R. Schall
  • H. K. L. Hundt
  • E. M. Mogilnicka
  • P. C. Beneke
Short Communication Drug Interactions

Keywords

Lansoprazole Pantoprazole Drug Invest Roxithromycin Hormonal Contraceptive 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fazio A. Oral contraceptive drug interactions: important considerations. South Med J 1991; 84: 997–1002PubMedCrossRefGoogle Scholar
  2. 2.
    Murad F, Kuret JA. Estrogens and progestins. In: Gilman, Rall, Nies, et al. editors. The pharmacological basis of therapeutics. New York: Pergamon Press, 1990: 1402–9Google Scholar
  3. 3.
    De Mey C, Meineke I, Steinijans VW, et al. Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. Int J Clin Pharmacol Ther Toxicol 1994; 32: 98–106Google Scholar
  4. 4.
    Gugler R, Hartmann M, Rudi J, et al. Lack of interaction of pantoprazole and diazepam in man [abstract]. Gastroenterology 1992; 102: A77Google Scholar
  5. 5.
    Hartmann M, Huber R, Bliesath H, et al. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man. Management of acid-related diseases: focus on pantoprazole. Berlin: Congress Abstracts Charité, 1993: 34–5Google Scholar
  6. 6.
    Schulz H-U, Hartmann M, Steinijans VW, et al. Lack of influence of pantoprazole on the disposition kinetics of theophylline in man. Int J Clin Pharmacol Ther Toxicol 1991; 29: 369–75PubMedGoogle Scholar
  7. 7.
    De la Rey N, Schall R, Luus HG, et al. Assessing the risk of ovulation in interaction studies of drugs and oral contraceptives. Int J Clin Pharmacol Ther Toxicol 1993; 31: 435–9PubMedGoogle Scholar
  8. 8.
    Meyer BH, Müller FO, Luus H, et al. A model to investigate interactions obtunding oral contraceptive activity. Med Sci Res 1987; 15: 1497Google Scholar
  9. 9.
    Meyer B, Müller F, Wessels P, et al. A model to detect interactions between roxithromycin and oral contraceptives. Clin Pharmacol Ther 1990; 47: 671–4PubMedCrossRefGoogle Scholar
  10. 10.
    CPMP Working Party on Efficacy of Medicinal Products. EEC Note for Guidance: good clinical practice for trials on medicinal products in the European Community. Pharmacol Toxicol 1990; 67: 361–72CrossRefGoogle Scholar
  11. 11.
    Trounson AO, Calabrese R. Changes in plasma progesterone concentrations around the time of the luteinizing hormone surge in women superovulated for in vitro fertilization. J Clin Endocrinol Metab 1984; 59: 1075–80PubMedCrossRefGoogle Scholar
  12. 12.
    Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991; 21: 195–212PubMedCrossRefGoogle Scholar
  13. 13.
    Bliesath H, Huber R, Hartmann M, et al. Pantoprazole does not influence the steady-state pharmacokinetics of nifedipine. Gastroenterology 1994; 106 Suppl. In pressGoogle Scholar
  14. 14.
    Colin-Jones DG. Safety of lansoprazole. Aliment Pharmacol Ther 1993; 7: 56–60PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • M. V. Middle
    • 1
  • F. O. Müller
    • 1
  • R. Schall
    • 1
  • H. K. L. Hundt
    • 1
  • E. M. Mogilnicka
    • 1
  • P. C. Beneke
    • 1
  1. 1.FARMOVS Institute for Clinical Pharmacology and Drug Development, Department of PharmacologyUniversity of the Orange Free StateBloemfonteinSouth Africa

Personalised recommendations